Literature DB >> 8458181

Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients.

E McCorvey1, J T Wright, J P Culbert, J M McKenney, J D Proctor, M P Annett.   

Abstract

The effect of hydrochlorothiazide, propranolol, and enalapril on cognitive and motor function and quality of life (QOL) in hypertensive patients was studied. Patients > or = 55 years of age with asymptomatic essential hypertension were included in a randomized, double-blind, placebo-controlled, crossover study. Subjects discontinued their previous antihypertensive agents and started hydrochlorothiazide 25 mg, extended-release propranolol hydrochloride 120 mg, enalapril maleate 10 mg, or placebo. One capsule was taken for three days and then the dosage was doubled for the remainder of a four-week period. Subsequent crossover treatments were begun without a washout period. In each treatment phase, a battery of psychometric tests was used to assess cognitive and motor function and quality of life; all tests but one were self-administered via computer terminal. Pulse rate and blood pressure were recorded, and compliance was monitored by capsule count. Sixteen of 30 patients interviewed completed the trials; one additional patient was evaluated after receiving all treatments except hydrochlorothiazide. Mean +/- S.D. age of the subjects was 66 +/- 6.1 years; 10 were black and 7 white; 9 were men. Except for the hydrochlorothiazide group, blood pressure in the active treatment groups did not differ significantly from placebo; hydrochlorothiazide significantly reduced systolic but not diastolic blood pressure compared with placebo. Compared with placebo, hydrochlorothiazide was associated with fewer incorrect responses in a test of complex reaction time and with greater discriminant reaction time response rates; otherwise, no difference between groups was noted in cognitive or motor performance. There were no significant differences between active treatments and placebo on individual QOL measures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458181

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  7 in total

Review 1.  Cost-effective therapy for hypertension.

Authors:  W Barrie
Journal:  West J Med       Date:  1996-04

Review 2.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 3.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 4.  The effects of ACE inhibitors on cognitive function.

Authors:  A A O'Brien; C J Bulpitt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

5.  Quality of life bibliography and indexes: 1993 update.

Authors:  R A Berzon; G P Simeon; R L Simpson; M A Donnelly; H H Tilson
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

6.  Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study.

Authors:  Sevil Yasar; Fu-Mei Lin; Linda P Fried; Claudia H Kawas; Kaycee M Sink; Steven T DeKosky; Michelle C Carlson
Journal:  Alzheimers Dement       Date:  2012-03-30       Impact factor: 21.566

Review 7.  Quality of life and treatment adherence in hypertensive patients: systematic review with meta-analysis.

Authors:  Ana Célia Caetano de Souza; José Wicto Pereira Borges; Thereza Maria Magalhães Moreira
Journal:  Rev Saude Publica       Date:  2016-12-22       Impact factor: 2.106

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.